multiple sclerosis/tyrosine

Study duration will vary per participant in this event driven trial with a treatment duration of approximately 24 to 48 months.

Study duration will vary per participant in this event driven trial with a treatment duration of approximately 24 to 48 months.

Study duration will vary per participant in this event driven trial with a treatment duration of approximately 18 to 36 months.

Study duration will vary per participant in this event driven trial with a treatment duration of approximately 18 to 36 months.

Test plan overview Project phase Phase II Indication: Complementary treatment of COVID 19 The purpose of the study: Examine the efficacy and tolerance of a chlorine dioxide based preparation Study design: Quasi-experimental clinical case study Number of patients expected: 20 patients. Main inclusion

This is a phase I clinical trial to evaluate the safety, tolerability, and maximum tolerated dose of DMF in patients with chronic lymphocytic leukemia. Patients with relapsed/refractory CLL not amenable to available therapies are eligible. This patient population is in need of novel therapies,

Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective effect through its activity on mast cells and other non-neuronal cells of the central nervous system, with subsequent modulation of inflammatory and neurodegenerative processes. The objective of this study

The immune and clinical impacts of vitamin D in patients with chronic musculo-skeletal pain Background Vitamin D is a group of fat-soluble secosteroids, the two major physiologically relevant forms are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D without a subscript refers

Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have many overlapping clinical features. The diseases are clonal stem cell disorders characterized by a chronic excess